Jaume Capdevila
Expertise in
15
conditions

Jaume Capdevila

Barcelona, CT, ES 
Expertise in
15
conditions
Barcelona, CT, ES 

Overview

Jaume Capdevila practices practicing medicine in Barcelona, Spain.

Capdevila is highly rated in 15 conditions, according to our data. Their clinical expertise encompasses Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Thyroid Cancer, and Medullary Thyroid Carcinoma.

They are actively involved in clinical research, co-authoring 203 peer reviewed articles and participating in 10 clinical trials.

Locations

Barcelona, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Drug
Study Drugs: CAM2029, Octreotide LAR, Lanreotide ATG
Study Phase: Phase 3
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
A Phase 1/2 Trial of a Novel Therapeutic Vaccine (EO2401) in Combination With Immune Check Point Blockade, for Treatment of Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma
Enrollment Status: Terminated
Publish Date: January 30, 2026
Intervention Type: Biological
Study Drugs: EO2041, Nivolumab
Study Phase: Phase 1/Phase 2
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drug: Surufatinib
Study Phase: Phase 2
Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)
Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)
Enrollment Status: Completed
Publish Date: July 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drug: STZ-5FU
Study Phase: Phase 3
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (the DUNE Trial)
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (the DUNE Trial)
Enrollment Status: Completed
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
A Phase III Clinical Trial Evaluating TheraSphere® in Patients With Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Enrollment Status: Completed
Publish Date: March 29, 2022
Intervention Type: Device
Study Phase: Not Applicable
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)
Enrollment Status: Completed
Publish Date: July 27, 2020
Intervention Type: Drug
Study Phase: Phase 2
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria
Enrollment Status: Completed
Publish Date: March 24, 2020
View 9 Less Clinical Trials

203 Total Publications

Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Correction: A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217).
Journal: BMC cancer
Published: June 13, 2026

Frequently Asked Questions about Jaume Capdevila

Is Jaume Capdevila a top-rated expert for Neuroendocrine Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Jaume Capdevila is classified as an Elite expert for Neuroendocrine Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jaume Capdevila participate in research or clinical trials?

Yes. Jaume Capdevila has published 203 articles and abstracts on conditions like Neuroendocrine Tumor. You can view a list of Jaume Capdevila's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Capdevila's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile